Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
StockNews.AI • 3 hours
High Materiality8/10
Information
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody
Original sourceAI Summary
Harbour BioMed has acquired a 3.8% stake in Spruce Biosciences, strengthening their strategic collaboration to advance SPR202, a monoclonal antibody targeting various disorders. This move signifies a deepening relationship and may enhance development timelines for innovative therapeutic solutions.
Sentiment Rationale
The acquisition enhances market confidence in SPRB, reminiscent of past successful biotech partnerships that drove stock values higher.
Trading Thesis
Bullish on SPRB due to strategic partnership with Harbour BioMed, likely short-term price boost.
Market-Moving
- Harbour's acquisition could signal increased investor confidence.
- The strategic partnership may accelerate SPR202's development, influencing market sentiment.
- Potential growth in sales and market share with successful SPR202 launch.
- Increased focus on transformative therapies could drive future investments.
Key Facts
- Harbour BioMed acquires 3.8% of Spruce Biosciences.
- Warrant exercised marks deeper strategic collaboration.
- Collaboration focuses on developing monoclonal antibody SPR202.
- CEO emphasizes shared commitment to transformative therapies.
- Partnership enhances potential for accelerated drug development.
Companies Mentioned
- Harbour BioMed (HKEX: 02142): Harbour's acquisition elevates their influence in SPRB's strategic direction.
Corporate Developments
This news falls under 'Corporate Developments' as it signifies a strategic partnership that can substantially impact future therapy advancements.
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in Spruce Biosciences, Inc. (NASDAQ:SPRB) ("Spruce"). Following this transaction, Harbour BioMed holds approximately 3.8% of the total outstanding shares of Spruce and approximately 3.1% of the fully diluted shares of Spruce[1].
The warrant was originally issued to Harbour BioMed's subsidiary and other minority shareholders of HBM Alpha Therapeutics ("HBMAT"), an innovative biotechnology company incubated by Harbour BioMed, in connection with a license and collaboration agreement by and between HBMAT and Spruce. The collaboration aims to advance the development of SPR202 (formerly known as HBM9013 by Harbour BioMed), a potent and selective anti-corticotropin-releasing hormone monoclonal antibody for various disorders, including congenital adrenal hyperplasia.
Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, stated: "This warrant exercise marks a significant milestone in our relationship with Spruce Biosciences. It moves us beyond a traditional licensor-licensee relationship to a truly aligned strategic partnership, reinforcing our shared commitment to accelerating the development of transformative therapies for patients worldwide."
[1] Calculated based on the total outstanding shares and fully diluted shares of Spruce as of September 30, 2025. |
About Harbour BioMed
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology. The company is building a robust and differentiated pipeline through internal R&D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions.
Harbour BioMed's proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. Additionally, the HCAb-based bispecific immune cell antagonist (HBICATM) technology empowers the development of innovative biologics for immunological and inflammatory diseases. By integrating Harbour Mice®, HBICE®, and HBICATM with a single B-cell cloning platform, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/harbour-biomed-acquires-common-stock-in-spruce-biosciences-deepening-strategic-collaboration-302664109.html
SOURCE Harbour BioMed